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The extracellular-regulated protein kinase 5 promotes macrophage 
proliferation associated with tumor growth and metastasis through 
controlling p21expression 
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The presence of immunosuppressive macrophages that become activated in the tumor 
microenvironment constitutes a major factor responsible for tumor growth and malignancy. 
In line with this knowledge, we report that macrophage proliferation is a significant feature of 
advanced stages of cancer. Moreover, we have found that a high proportion of proliferating 
macrophages in human tumors express ERK5. Importantly, genetic study in mice showed that 
ERK5 was required for supporting the proliferation of macrophages in tumor grafts. Further 
detailed analyses of metastatic lung nodules indicated that the proliferation of both, resident 
and infiltrated macrophages was negatively impacted by myeloid ERK5 deficiency. Our 
molecular investigations led us to propose that ERK5 maintained the capacity of 
macrophages to proliferate by suppressing p21 expression to halt their differentiation 
programme. Collectively, these data provide insight into the mechanism underpinning 
macrophage proliferation to support malignant tumor development, thereby strengthening the 
value of ERK5-targeted therapies to restore anti-tumor immunity through the blockade of 




Our study offers a new rational for anti-ERK5 therapy to improve cancer patient outcomes 






Tumor-associated macrophages (TAMs) are the most abundant cell types across the 
majority of cancers analyzed (1). Their exquisite ability to shape their phenotype in response 
to external stimuli allows them to exhibit multifaceted functions in the tumor 
microenvironments (TME) (2). In particular, as tumors progress, cancer cells produce 
signals that educate TAMs to secrete a variety of cytokines, growth factors, inflammatory 
substrates and proteolytic enzymes involved in cancer progression, malignancy and 
resistance to standard-of-care therapeutic interventions (2, 3). Accordingly, TAM abundance 
has been associated with worse patient prognosis in many, if not all, solid tumors (4, 5). 
Hence, there has been significant interest in devising macrophage-centered approaches for 
cancer treatment (2, 3, 6, 7). However, the potential of efficient tailored TAM-directed 
therapies will only be revealed once the full spectrum of molecular mechanisms governing 
the programming of pro-tumoral macrophages is discovered. 
As a representative example, we have recently analyzed the phenotypic consequences 
of selective ablation of the extracellular-regulated protein kinase 5 (ERK5) in the myeloid 
lineage (8). ERK5 belongs to the family of mitogen-activated protein kinases (MAPKs) that 
play key roles in transducing extracellular cues into a wide variety of cellular responses, 
including changes in gene expression (9). Like other MAPKs, ERK5 is activated upon 
stimulation by dual phosphorylation of the canonical MAPK activation motif Thr-Glu-Tyr by 
the MAPK/ERK kinase 5 (MEK5). Nonetheless, ERK5 is very different from the other 
members of the MAPK family due to a unique extended C-terminal tail (9). The importance 
of ERK5 in signal transduction is further supported by compelling genetic evidence that the 
pathway exerts non-redundant functions in vivo (10). Notably, we found that ERK5 was 
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required for TAM education by cancer cells (8). Coincidentally, myeloid ERK5 deficiency 
impaired the growth of 4434 melanoma and Lewis lung adenocarcinoma (LL2) tumor grafts 
in mice (8). The tumor growth defect caused by the absence of ERK5 correlated with reduced 
TAM density, in addition to abnormal macrophage polarization (8).  
There is compelling evidence that TAM accumulation is a consequence of the constant 
recruitment of circulating monocytic precursors in the blood, originating from 
hematopoietic stem cells (HSCs) in the bone marrow (11-13). However, other studies 
revealed that TAMs could also originate from tissue resident macrophages derived from the 
embryonic yolk sac (14, 15). Furthermore, macrophages in tumor retain the capacity to 
proliferate (13, 16-19). This unique feature was shown to markedly contribute to increasing 
the pool of pro-tumoral  TAMs, whether they derive from the yolk sac or the bone marrow, in 
mammary (13) and pancreatic (20) tumors. Colony stimulating factor 1 (CSF1, also known as 
M-CSF) is one of the main factor produced by tumor cells to control the number of TAMs in 
the TME through stimulation of the CSF1 receptor (21). A previous study showed that CSF1 
exerted its mitogenic effect upon binding to the CSF1 receptor and the stimulation of ERK5 
in macrophages (22). On the basis of these data, we sought to investigate the impact of ERK5 
on TAM proliferation as an important mechanism by which tumor-educated macrophages 
exhibiting protumoral phenotypes and functions accumulate in the TME.  
 
MATERIALS AND METHODS  
 
Animal welfare and human samples  
Mice were maintained in a pathogen-free facility at the University of Manchester. All animal 
procedures were performed under license in accordance with the UK Home Office Animals 
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(Scientific Procedures) Act (1986) and approved by the Animal Welfare and Ethical Review 
Body of the University of Manchester, UK. In particular, mice with tumors were closely 
monitored by careful clinical examination to allow detection of deterioration of their physical 
condition. Animals showing signs of distress were sacrificed before any further deterioration 
in condition occurred. Formalin-fixed paraffin-embedded (FFPE) human tissues obtained 
with appropriate consents were retrieved from the tissue bank of the Department of Pathology 
(ASST Spedali Civili di Brescia, Brescia, Italy) 
 
Immunohistochemical analyses of human tissues 
Four-micron thick sections were double immunostained with antibodies to Ki67 
(undiluted; clone 30-9 from Roche) and to CD163 (1:50 dilution; clone 10D6 from Thermo 
Scientific). Ki67 was revealed using Novolink Polymer (Leica Biosystems) followed by 
DAB. After completing the first immune reaction,  antibodies to CD163 (1:50 dilution; clone 
10D6 from Thermo Scientific), CD3 (dilution 1:80, clone LN10 from Leica Biosystems), 
CD20 (dilution 1:250, clone L26 from Leica Biosystems), CD117 (dilution 1:100, polyclonal 
from Agilent) or CD66b (dilution 1:150, clone G10F5 from Novus Biologicals) were 
visualized using Mach 4 MR-AP (Biocare Medical), followed by Ferangi Blue (Biocare 
Medical) as chromogen. For triple immunohistochemistry, after completing the second 
immune reactions (Ki67/CD163 or ERK5/CD163) antibody to CD31 (1:30 dilution; clone 
JC70A from Leica Biosystems) was applied and visualized using Dako REAL Detection 
System, Alkaline Phoshatase/RED (Agilent). Slides were subsequently counterstained with 
hematoxylin. Sequentially double immunostaining was performed using a non-permanent 
chromogen (AEC) to reveal Ki67. The slides were counterstained with hematoxylin. After 
digitalization using Aperio Scanscope CS (Leica Mycrosystems), slides were decolored and 
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the Ki67 antibody was stripped using a 2-mercaptoethanol/SDS solution (20 ml 10% w/v 
SDS with 12.5 ml 0.5 M Tris-HCl, pH6.8, 67.5 ml distilled water and 0.8 ml 2-ME) in a 
water-bath pre-heated at 56°C for 30 min. Sections were washed for 1 h in Tris-HCl. Then, 
after antigen retrieval, anti-ERK5 (1:100 dilution; clone C-20 from Santa Cruz 
Biotechnology) was applied on the slides and revealed using Novolink polymer followed by 
DAB. An anti-CD163 was subsequently utilized to localize TAMs (as described above). 
Slides were newly cover-slipped, digitalized and then the two digital slides were processed 
using synchronizing tool of ImageScope. Snapshots of 400X where taken from the two scans 
and corresponding tissue regions were analyzed using the counter tool. Overlapping of the 
single images where obtained using Adobe Photoshop. 
 
Mice 
Mice were identified by PCR on genomic DNA, as previously described (8). For 
melanoma grafts, 4434 melanoma cells were subcutaneously transplanted in the flanks of 8-
12 weeks old syngeneic C57Bl/6 mice (8). For lung experimental metastasis, 2 × 10
5
 B16F10 
melanoma cells resuspended in 0.1 ml PBS were injected via the lateral tail vein using a 27-
gauge needle. Mice were killed between 15 and 20 days after injection and tissues were 
isolated and fixed in 10% neutral-buffered formalin, prior to being processed for 
immunofluorescence analysis as previously described (8). Sections were counterstained with 
H&E and surface metastatic foci in lung left lobes were counted under a dissecting 
microscope. For quantitation of metastatic nodule size, photos of random fields were obtained 
(using low-magnitude 4x and 10x lens), and then the sizes of at least 20 nodules were 






Mononuclear single-cell suspensions from mouse tumors, lungs and spleen were 
obtained as indicated in the Supplemental Data available with this article online 
(Supplementary Methods) and analyzed by fluorescence-activated cell sorting (FACS), as 
previously described (8). Antibodies utilized for flow cytometry analysis and magnetic bead 
purification are provided in the Supplementary Methods. For determining cell proliferation, 
primary bone derived macrophages were pulse labelled in vitro with 100 µM 5-bromo-2’-
deoxyuridine (BrdU) (Sigma) for 30 min at 37°C. Cells were subsequently harvested, fixed in 
4% formaldehyde for 15 min at room temperature, and permeabilized by incubation in ice-
cold methanol for 30 min. Cells were washed in PBS and incubated with a primary antibody 
to BrdU (1:200 dilution; CST#5292) for 60 min, followed by incubation with a secondary 
Alexa Fluor 488-conjugated anti-mouse IgG F(ab’)2 fragment (1:100 dilution; CST#4408) 
for 30 min at room temperature.  
 
Immunoblot analysis of bone marrow derived macrophages 
Primary murine macrophages were obtained from bone marrow cells isolated from 
femurs of wild type or genetically modified mice and polarized by exposure to tumor cell-












, respectively. Proteins (30 g) were subsequently extracted in RIPA buffer, 
resolved by SDS-polyacrylamide gel electrophoresis and transferred to an Immobilon-P 
membrane (Millipore, Inc.). The membranes were saturated in 3% non-fat dry milk and 
probed overnight at 4
o
C with antibodies to ERK5 (1:1000 dilution; CST3372), p21 (1:1000 
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dilution; CST2947) or tubulin (1:1000 dilution; CST2125). Immuno-complexes were 
detected by enhanced chemiluminescence with immunoglobulin G coupled to horseradish 
peroxidase as the secondary antibody (GE Healthcare).  
 
Quantitative real-time PCR  
Total RNA was reversed transcribed and quantified by RT-PCR using the SYBR Green 
I Core Kit (Eurogentec), as described previously (8). Sequences of the forward and reverse 
primers are indicated in the Supplemental Data available with this article online 
(Supplementary Table S1). Results were analyzed using the 2
-G
 method. The level of 
expression of mRNA was normalized to Gapdh and Pgk1 mRNA. 
 
Statistical analysis 
All p values were generated using an unpaired student's t-test and one-way ANOVA 
with Tukey’s correction for multiple comparisons. Data were analyzed using Prism software 




The authors declare that all data supporting the findings of this study are available 
within the article and its supplementary information files or from the corresponding authors 









Human neoplastic tissues comprise high numbers of proliferative 
macrophages 
To demonstrate that proliferating TAMs were characteristic of human cancer, we 
initially screened a large set of human primary malignant lesions (n = 197) using tissue 





 cells) in squamous cell carcinoma (SCC), lung 
adenocarcinoma and breast carcinoma compared with normal tissues (Fig. 1A-I). This was 
confirmed by quantitative analysis of Ki67
+





as well as the total number of macrophages are included in Supplementary Table S2. 
Likewise, a high number of proliferating TAMs was detected in primary human 
hepatocarcinoma, colon, ovary, bladder carcinoma, melanoma, mesothelioma, and metastatic 
melanoma and carcinoma (Supplementary Fig. S1). To explore the possibility that 
macrophage accumulation through proliferation was a significant feature of malignancy, we 




 macrophages in human melanoma at different stages 
of tumor progression. These included benign nevus (Fig. 2A and B), early (pT1a) and late 
(pT4b) stage primary cutaneous melanoma (PCM) (Fig. 2C-F), and dermal metastasis of 
cutaneous melanoma (MM; Fig. 2G and H). Remarkably, we observed that the percentage of 
proliferating TAMs significantly increased as the disease progressed (Fig 2I and 
Supplementary Table S2). In contrast, no marked difference was observed between benign 
nevus and normal skin tissues. Together, these observations clearly indicated that local 
10 
 
macrophage proliferation was a common hallmark of human tumors and a potentially 
important prognostic marker of malignancy.  
 
Tumor macrophage proliferation is dependent on ERK5 
We had previously found that macrophage density was markedly reduced in carcinoma 
grafts derived from myeloid ERK5 deficient mice compared with controls (8). Utilizing a 
similar approach based on our LysM-Cre;erk5
F/F
 model, we confirmed that the number of 
TAMs in melanoma grafts decreased by almost 2 fold in the absence of ERK5 





expressing CD206 was reduced in melanoma grafts derived from LysMCre;erk5
F/F
 mice 
compared to that from erk5
F/F
 (Supplementary Fig. S2C-E). Importantly, the reduction in 
macrophage density caused by myeloid ERK5 deficiency coincided with reduced melanoma 
cell proliferation in the tumor (Supplementary Fig. S3). 
Based on these data, we examined a possible association between ERK5 expression and 
tumor macrophage proliferation in human cancer. This was achieved by employing Aperio 
Scanscope digitalization to sequentially detect Ki67 (AEC) and ERK5 (brown) in CD163
+ 
(blue) cells in human tumor sections. Between 60% and 50% of proliferating TAMs in lung 
metastasis of cutaneous melanoma and ovarian carcinoma expressed ERK5 in the nucleus 





macrophages present in cell blocks of pleural effusion of lung adenocarcinoma (Fig. 3G-I) 
and cytospin preparation of peritoneal wash of ovarian carcinoma (Fig. 3J-L), respectively. 
Proliferating ERK5
+
 macrophages were found in both, intra-tumoral area (cutaneous 
melanoma) and intra-tumoral stroma (2
nd
 raw ovarian carcinoma). Further analyses of breast 




 macrophages in peri-tumoral area, 
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close to tumor vessel at the invasion edge (Supplementary Fig. S4). Based on these 
observations, we concluded that human tumors comprised a high proportion of proliferating 
TAMs expressing ERK5 scattered around the tissue. Unlike TAMs, CD117
+ 
mast cells and 
CD66b
+ 
neutrophils exhibited a predominantly cytoplasmic ERK5 staining, indicative of a 





B cells was very low, suggesting that ERK5 might not 
play a critical role in the adaptive immune system of the tumor microenvironment 
(Supplementary Fig. S5).  
To establish whether ERK5 was required for mediating tumor macrophage 
proliferation, we sought to analyze the impact of myeloid ERK5 deficiency in excised murine 
melanoma and carcinoma grafts. Tumor sections were processed by immunofluorescence 
staining with antibodies to Ki67 and to Iba1, a commonly used cell surface marker to label 





 macrophages in tumors derived from LysM-Cre;erk5
F/F
 mice compared with 
erk5
F/F
 controls (Fig. 4A and B and Supplementary Fig. S6A and B). Moreover, ERK5 
deficient macrophages purified from melanoma or carcinoma grafts expressed a lower level 
of positive regulators of cell proliferation, e.g. Ets2, Ki67 and c-Jun transcripts, compared 
with wild type cells (Fig. 4C and Supplementary Fig. S6C). Conversely, carcinoma 
macrophages lacking ERK5 exhibited increased mRNA expression of two important 
transcription factors associated with macrophage differentiation, namely c-Maf and MafB 
(Supplementary Fig. S6C). A similar increase in c-Maf level was detected in purified ERK5 
deficient macrophages from melanoma, although no significant difference was observed in 
MafB expression (Fig. 4C). Additionally, the cyclin-dependent protein kinase inhibitor p21 
was significantly upregulated in the absence of ERK5 (Fig. 4C and Supplementary Fig. S6C). 
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We confirmed by immunoblot analysis that p21 protein level was noticeably increased in 
LysM-Cre;erk5
F/F
 macrophages polarized in vitro by incubation with melanoma 4434 cell-
conditioned medium (Supplementary Fig. S7A). This coincided with increased p53 
expression and decreased level of pSTAT3(Tyr705) and cyclin D1. In contrast, the absence 
of ERK5 did not affect ERK1/2 (Supplementary Fig. S7A). 
 
ERK5 is a key suppressor of p21 expression during the maturation and 
differentiation of monocytes into macrophages 
To provide direct evidence that ERK5 was a positive regulator of TAM proliferation, 





mice  to permit inducible erk5 deletion in vitro by incubation with 4-HT (Supplementary Fig. 
S7B). Initially, we confirmed by short-term BrdU incorporation that non-polarized (NP) 
macrophages in steady state were mostly quiescent, whilst more than 20% of macrophages 
polarized by incubation with 4434 melanoma cell-conditioned media (4434-CM) were 
actively replicating their DNA (Fig. 4D). Increased tumor macrophage proliferation was 
clearly reduced in the absence of ERK5 (Fig. 4D). Accordingly, polarized erk5

 
macrophages exhibited a much lower level of Ki67 transcript compared with wild type cells 
(Fig. 4E). This correlated with a significant upregulation of p21 at mRNA and protein level 
(Fig. 4E and F). These results led us to conclude that ERK5 was required for mediating the 
mitogenic response of macrophages to tumor soluble factors, at least in part, via suppressing 
p21 expression. 
We and others had previously observed that functional disruption of ERK5 signaling 
advanced macrophage differentiation in vitro (8, 23). Therefore, we tested whether the 
mitogenic effect of ERK5 was a consequence of its ability to suppress differentiation. 
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Consistent with our previous data, ERK5 ablation in bone marrow cells impaired the ability 
of maturing macrophages to proliferate (Fig. 5A and Supplementary Fig. S7C and D). 
Moreover, the absence of ERK5 significantly accelerated the kinetic of monocyte 
differentiation in vitro (Fig. 5B and C). Notably, the intensity of F4/80 and CD115 staining 




 maturing macrophages at day 3, 
indicative of a more advanced macrophage differentiation in the absence of ERK5 (Fig. 5C 
and D). Interestingly, the differentiation of erk5

 monocytes was associated with a strong 
upregulation of p21 expression (Fig. 5E). Given that p21 is crucial for the maturation and 
differentiation of macrophages (24, 25), we proposed that the downregulation of p21 
expression by ERK5 constituted one potentially important mechanism that maintains 
macrophages in a phenotypic state capable of responding to mitogenic factors produced by 
cancer cells (Fig. 5F).  
 
Inhibition of ERK5 activity blocks tumor macrophage proliferation  
The detection of an electrophoretic migratory shift characteristic of ERK5 
phosphorylation provided evidence that ERK5 was activated in macrophages stimulated with 
4434-CM or B16F10-CM (Supplementary Fig. S8A). Accordingly, pre-incubation with the 
JWG-045 compound caused the disappearance of the slow migrating band as a consequence 
of inhibition of ERK5 activity and the loss of C terminal tail autophosphorylation 
(Supplementary Fig. S8A). In contrast, JWG-045 did not affect ERK1/2 phosphorylation. 
Similar to the loss of ERK5 protein expression, inhibition of ERK5 by JWG-045 reduced by 
half the number of proliferating tumor macrophages (Supplementary Fig. S8B and C). 
However, given that the first generation of pharmacological ERK5 inhibitors exhibited non-
specific effect on BRD4 proteins (26), we wanted to insure that ERK5 activation was 
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essential for promoting the proliferation of TAMs by other means. Therefore, erk5

 
macrophages were co-infected with adenoviruses encoding Ha-tagged constitutive active (ca) 
MEK5 and flag-tagged (F) wild type (WT) or dominant negative mutant (AEF) ERK5 
(Supplementary  Fig. S9A). As expected, ERK5(AEF) did not display the mobility 
retardation shift characteristic of ERK5(WT) phosphorylation by caMEK5 (Supplementary  
Fig. S9B). Moreover, unlike ERK5(WT), ERK5(AEF) expressed together with caMEK5 
significantly reduced the number of proliferating macrophages exposed to 4434-CM 
(Supplementary  Fig. S9C and D). Collectively, these data demonstrated that ERK5 
activation by MEK5 was critical for tumor-induced macrophage proliferation. 
 
ERK5-mediated macrophage proliferation supports melanoma tumor 
metastasis in vivo  
Given the correlation between TAM proliferation and melanoma invasiveness in human 
(Fig. 2), we sought to investigate the impact of myeloid ERK5 deficiency in metastasis. 





mice. Animals were sacrificed after 2 to 3 weeks and post-mortem analyses 
showed that the lungs of LysM-Cre;erk5
F/F
 mice exhibited less metastases compared with 
control erk5
F/F
 animals (Fig. 6A). Quantitative analysis indicated that the number of 
metastatic lung nodules was reduced by half in myeloid ERK5 deficient mice (Fig. 6B). To 





 transplanted mice were processed by haematoxylin 
and eosin (H&E) staining. Metastatic foci in both groups were distributed as perivascular and 
subpleural lesions (Fig. 6C). However, consistent with our previous macroscopic observation, 
their number and size were significantly lower in the absence of ERK5 (Fig. 6C and D). 
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Immunofluorescence analysis of lung tissue sections with an antibody to Iba1 confirmed that 
ERK5 ablation significantly reduced TAM density in melanoma metastases (Supplementary 
Fig. S10). Accordingly, the lung of B16-F10-bearing LysM-Cre;erk5
F/F
 animals exhibited a 




 macrophages (Fig. 6E and F). We also noted that, 





















 monocytes (supplementary Fig. S11A). Accordingly, myeloid ERK5 
deficiency significantly reduced the percentage of monocytes proliferating in the blood or in 
the bone marrow of B16F10 transplanted animals (supplementary Fig. S11B and C).  







were subsequently analyzed by flow cytometry to distinguish interstitial (infiltrating) from 
alveolar (resident) macrophages based on different level of expression of CD11b and Cd11c 
markers (27, 28). CD64 was utilized as an alternate marker to F4/80 to distinguish 







macrophages (supplementary Fig. S12A and B). Moreover, the 




 alveolar macrophages was unaffected by the absence of 
ERK5 (supplementary Fig. S12C and D). In contrast, the absence of ERK5 reduced the 









in metastatic lung nodules (Fig. 7A and B). F4/80
+
 cells were subsequently purified by 




 macrophages were analyzed 
separately by flow cytometry for Ki67 expression (supplementary Fig. S13A). We confirmed 
that F4/80+ sorted cells were positive for CD64 expression (supplementary Fig. S13B and C). 
Importantly, we found that myeloid ERK5 deficiency decreased the number of proliferating 
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metastatic lung interstitial (Fig. 7C and D) and alveolar (Fig. 7E and F) macrophages. 
Together, these findings provided a further compelling demonstration that ERK5-mediated 




Targeted therapies aimed at depleting macrophages in the tumor microenvironment 
have been actively pursued to combat various cancers (2, 3, 6, 7). One of the most advance 
approaches rely on the blockade of CSF1/CSF1 receptor, given that CSF1 is highly expressed 
in several types of human tumors with poor patient outcomes and the dominant role of this 
signaling pathway in fostering the development of various populations of macrophages 
exhibiting pro-tumor properties (29, 30). In particular, in mammary cancer, CSF1 produced 
by tumor cells was shown to drive the accumulation of TAMs that supply the neoplasm with 
the crucial epidermal growth factor (EGF) (31). This was consistent with an earlier study 
which demonstrated that the genetic loss of csf1 significantly reduced metastasis in mammary 
tumors (32). Importantly, while less effective, neutralizing CSF1 in breast cancer xenografts 
decreased tumor growth (33). Further studies confirmed that depleting TAMs by CSF1R 
signaling blockade delayed tumor progression and reduced metastasis, but also enhanced the 
efficacy of several other standard therapies in various murine models of solid tumors (30).  
However, despite these promising results, clinical trials have brought modest clinical 
benefits for cancer patients, emphasizing the necessity for far more in depth understanding of 
the mechanisms underpinning the accumulation of pro-tumoral macrophage populations in 
pre-clinical settings. In particular, despite being differentiated, macrophages preserve a 
certain capacity to self-renew in response to various environmental cues (34). This is 
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significant given that subsets of TAMs were observed to proliferate in sarcomas (17), breast 
carcinomas (13, 18, 19) and pancreatic cancer (20). Furthermore, there is a possibility that 
increased macrophage proliferation following the cessation of TAM depletion contributes to 
accelerating tumor growth in a murine model of breast cancer metastasis (35). Our 
demonstration that macrophage proliferation was a common feature of cancer patients 
across various malignant tumor types added further weight to the idea that pools of 
macrophages can expand through local self-renewal in tumor tissue. Consistent with 
evidence that TAM density positively correlates with the malignant progression of most solid 
tumors (2-5), including melanoma (36, 37), decreased TAM proliferation caused by myeloid 
ERK5 ablation halted the growth of murine melanoma graft (8) and the capacity of melanoma 
cells to form lung metastasis.  
Based on previous analyses of ERK5 in cancer cells, ERK5 activity may promote 
macrophage proliferation by suppressing p53-mediated transcriptional upregulation of p21 
through blocking PML-dependent sequestration of MDM2 in cancer cells (38, 39). Further 
experiments will need to be conducted to provide a definite molecular link between p53 and 
p21 in ERK5-deficient macrophages, given that p21 can be induced via both p53-dependent 
and -independent mechanisms (40). For example, we have previously proposed that ERK5 
blocked p21 upregulation through c-Myc-dependent transcriptional regulation of miR-17-5p 
and miR-20a in breast cancer cells (41). Moreover, in light of previous evidence that p21 was 
crucial for the maturation and differentiation of macrophages (24, 25), we anticipate that 
ERK5 supports macrophage proliferation through blocking differentiation, rather than having 
a direct effect on the cell cycle. This model is consistent with our demonstration that ERK5-
deficient monocytes/macrophages exhibiting a high level of p21 differentiated more rapidly. 
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The requirement of ERK5 to regulate the level of p21 might also be responsible for causing 
increased STAT3 signaling and the acquisition of pro-tumorigenic TAM phenotypes (8, 42) 
Mechanistically, the ability of ERK5 to block macrophage differentiation might involve 
decreased expression of transcription factors of the Maf family, given that cMaf/MafB 
deficiency rendered functionally differentiated macrophages capable of expanding through 
self-renewal via KLF4 and c-Myc (43). Consistently, a further analysis demonstrated that 
transient down-regulation of Maf transcription factors was required for proliferating resident 
macrophages (44). Moreover, both KLF4 and c-Myc, which have been implicated in 
pluripotent stem cell reprogramming (45), are ERK5 targets (46, 47). However, a recent 
study showed that cMaf was a transcriptional regulator of pro-tumoral macrophage activation 
(48). In the future, unbiased transcriptomic studies to establish the transcriptional network 
downstream of ERK5 will be essential to understand how ERK5 maintains proliferative pro-
tumor macrophage populations to support tumor progression and malignancy. In particular, 
these data will clarify the requirement of Maf factors downstream of ERK5 and may reveal 
potential important functional cross talks between p21, Maf and STAT3 implicated in pro-
tumoral macrophage polarization. 
In summary, we demonstrate in this study that TAM proliferation is a general 
mechanism in cancer. Moreover, we provide a novel insight into TAM self-renewal with the 
potential clinical implication of pharmacological inhibition of ERK5, alone or combined with 
other therapeutic strategies based on blocking the survival or the recruitment of macrophages 
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Figure 1. Human tumors contain a high number of proliferating macrophages. Sections from 
normal and neoplastic tissues, including skin (A-C), lung (D-F) and breast (G-I), were 
double stained for Ki67 (brown) and CD163 (blue). Original magnification: 200x (scale bar 
100 m; A, B, D, E, G, H) and 600x (scale bar 33 m; C, F, I). Arrows in 200x highlight 





were counted (at least 100 macrophages/case) in normal skin (n = 5), cutaneous squamous 
cell carcinoma (n = 11), normal lung (n = 4), lung adenocarcinoma (n = 10), normal breast (n 
= 4), and breast carcinoma (n = 12). The data presented as percentage of proliferating 
macrophages (J- L) correspond to the mean ± SD. * p < 0.05, ** p < 0.01 compares normal 
versus tumor tissues.  
 
Figure 2. Proliferating TAMs in primary and metastatic melanomas. Sections from benign 
nevus (A, B), primary cutaneous melanoma (PCM; C-F) at different pathological stages and 
dermal metastasis of cutaneous melanoma (MM; G, H) were double stained for Ki67 (brown) 
and CD163 (blue). Original magnification: 100x (scale bar 200 m; A, C, E, G) and 400x 
(scale bar 50 m; B, D, F, H). I, The clinical significance of TAM proliferation in 





) in benign nevi (n = 10), PCM (n = 20), and MM (n = 10). The data presented 
as percentages of proliferating macrophages in the four pathological groups correspond to the 






Figure 3. Human proliferating TAMs express ERK5. Ki67 and ERK5 co-localization in 
TAMs was demonstrated by double sequential immunostaining in two bioptical [a lung 
metastasis of cutaneous melanoma (A-C) and a vaginal localization of ovarian carcinoma (D-
F)] and two cytological [a cell block of pleural effusion of lung adenocarcinoma (G-H) and a 
cytospin preparation of peritoneal wash of ovarian carcinoma (J-L)] samples. Slides were re-
digitalized and images were taken using synchronizing and snapshot tools (400x). False color 





co-expressing Ki67 and ERK5 are highlighted in yellow.  
 
Figure 4. Myeloid ERK5 is required for TAM proliferation. A, Immunofluorescence imaging 
of melanoma grafts sections stained for Iba1 (red) and Ki67 (green). DNA was stained with 





) in tumor grafts with ImageJ and C, qRT-PCR analysis of positive (Ets2, Ki-67, c-Jun) 




 sorted macrophages 




 mice. The data 





 mice. ns; indicates no significant difference. D, 
Histograms represent quantitative analysis of BrdU
+
 macrophages and E, qRT-PCR analysis 




 macrophages. The 
data correspond to the mean ± SD of three (D, E) independent experiments performed in 




 macrophages. F, Immunoblot analysis of 




 macrophages cultured for 9 days in vitro prior 




Figure 5. ERK5 suppresses macrophage differentiation through negative regulation of p21. 





 monocytes. The percentage of BrdU
+
 cells is indicated in the 














monocytes/macrophages. The level of expression of F4/80 and CD115 (MFI) is indicated in 
each histogram plot. Data are representative of at least two independent experiments. E, 
Immunoblot analyses show that ablation of ERK5 in monocytes/macrophages correlate with 
increased p21 expression. Tubulin expression was used as loading control. Similar results 
were obtained in two independent experiments. F, Schematic model illustrating how ERK5 
blocks macrophage differentiation by supressing p21 expression.  
 
Figure 6. Myeloid ERK5 supports melanoma tumor metastasis in vivo. A, Representative 
pictures of lungs bearing metastases 18 days after intravenous transplantation of B16F10 




 mice. B, Quantification of 
the number of lung metastases in mice. * p  < 0.01 indicates a significant difference between 
erk5
F/F
 and LysM-Cre; erk5
F/F
 (n = 10 animals per genotype). C, Representative H&E 
sections of lungs from erk5
F/F
 and LysM-Cre; erk5
F/F
 mice. Arrows point to metastatic foci. 
Scale bar, 200 μm. D, Size distributions of B16F10 metastatic foci. * p < 0.01 indicates a 




 (n = 14 animals per genotype). 
E, Representative flow-cytometry analysis and quantification of live (DAPI
-
) myeloid cell 
populations in the lung 18 days after transplantation of B16F10 melanoma cells. F, Graphical 







associated with lung metastasis excised from LysM-Cre;erk5
F/F
 animals. The data correspond 





 mice. ns; indicates no significant difference. 
 
Figure 7. ERK5 deficiency blocks alveolar and interstitial macrophage proliferation in 









 (interstitial) macrophages in the lung of mice 
18 days after transplantation of B16F10 melanoma cells. B, Graphical analysis of A showing 
a reduced percentage of alveolar and interstitial macrophages in the lungs of LysM-
Cre;erk5
F/F
 mice. The data correspond to the mean ± SD (n = 3 tumors). C-F, F4/80
+
 sorted 
macrophages from A were separately analyzed for the expression of CD11b, CD11c and 











) (E, F) macrophages are shown. The data 
correspond to the mean ± SD (n = 3 tumors). * p < 0.05 compares erk5
F/F 
and LysM-
Cre;erk5
F/F
 mice 
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